Effects of testosterone, 17beta-estradiol, and downstream estrogens on cytokine secretion from human leukocytes in the presence and absence of cortisol by Janele, D et al.
Effects of Testosterone, 17-Estradiol,
and Downstream Estrogens on Cytokine
Secretion from Human Leukocytes in the
Presence and Absence of Cortisol
DAVID JANELE,a THOMAS LANG,a SILVIA CAPELLINO,a MAURIZIO
CUTOLO,b JOSE ANTONIO P. DA SILVA,c AND RAINER H. STRAUBa
aLaboratory of Neuroendocrinoimmunology, Department of Internal Medicine I,
University Hospital, 93042 Regensburg, Germany
bDivision of Rheumatology, Department of Internal Medicine and Medical
Specialities, University of Genova, Genova, Italy
cDepartment of Medicine III and Rheumatology, Coimbra University Hospital,
Coimbra, Portugal
ABSTRACT: Estrogens at physiological concentrations are thought to
play an immune-stimulating role, whereas androgens have an anti-
inflammatory impact. However, their role on cytokine secretion in the
presence or absence of cortisol has not been investigated. Furthermore,
the role of hydroxylated estrogens downstream of 17-estradiol (E2) on
secretion of tumor necrosis factor (TNF) is not known. In this study on
peripheral blood leukocytes of healthy male subjects, we scrutinized the
influence of prior sex hormones (for 24 h) with and without later addi-
tion of cortisol (for another 24 h) on stimulated secretion of TNF, IL-2,
IL-4, IL-6, IL-10, and interferon- (IFN-). E2 stabilized or increased
immune stimuli–induced secretion of TNF, IL-2, IL-4, IL-6, IL-10, and
IFN in relation to testosterone. Testosterone, in contrast, inhibited (IL-
2, IL-4, IL-10) or tended to inhibit stimulated secretion of these cytokines
(TNF, IFN). This effect of E2 was pronounced at a concentration of
10−10 M (testosterone: 10−7 M) in the presence of cortisol. E2 (10−8 M,
10−10 M) and testosterone (10−7 M) did not change glucocorticoid re-
ceptor expression. The downstream estrogens 2OH-estradiol(one), 4OH-
estradiol(one), and 16OH-estradiol(one) did not stimulate TNF secretion
at 10−10 M, but even inhibited its secretion at 10−11 M. However, the com-
bination of 16OH-estradiol(one) on one side and 2OH-estradiol(one) or
4OH-estradiol(one) on the other side markedly stimulated TNF secretion
that was only observable in the presence of cortisol. In conclusion, at phys-
iological concentrations, E2 and a combination of downstream estrogens
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stabilized or increased immune stimuli–induced TNF secretion. These
effects are dependent on the presence of physiological concentrations of
cortisol. This study underlines the proinflammatory role of E2, which
is probably dependent on conversion to a proinflammatory cocktail of
downstream estrogens and the presence of cortisol.
KEYWORDS: testosterone; 17-estradiol; 2-hydroxyestrogens; 4-hydrox-
yestrogens; 16-hydroxyestrogens; cortisol; TNF; cytokines
INTRODUCTION
The pro- and anti-inflammatory effects of 17-estradiol (E2) and other
estrogens on secretion of proinflammatory cytokines have been a matter of
debate for two decades. Authors in the field of rheumatology investigated
estrogens in the context of a strong proinflammatory microenvironment and
came to the conclusion that estrogens most often exert a proinflammatory
influence on chronic inflammatory diseases, whereas androgens are considered
to be anti-inflammatory.1,2 The proinflammatory influence of estrogens was
regarded to be a major factor for the known female-to-male preponderance in
autoimmune diseases.1,3–5 On the other hand, researchers in the field of bone
research demonstrated inhibitory effects of estrogens on cytokine secretion
in a noninflamed microenvironment leading to osteoprotective effects.6,7 This
discrepancy probably depends on very different conversion of estrogens to
downstream metabolites.
A proinflammatory microenvironment leads to conversion of androgens to
E2 and downstream estrogens8 that are further converted to 16-hydroxylated
active estrogens but not to 2-hydroxylated endogenous anti-estrogens.9,10 In
contrast, in normal macrophages, conversion of androgens to estrogens is
much less pronounced and 16-hydroxylated estrogens were not detected.11
Furthermore, in osteopenic postmenopausal women without inflammation,
16-hydroxylated estrone levels are much lower and correlated positively with
bone mineral density, whereas levels of 2-hydroxylated anti-estrogens showed a
negative correlation with bone mineral density.12,13 This indicates that the rela-
tion of 16-hydroxylated to 2-hydroxylated estrogens is completely different in
chronic inflammatory diseases as compared to the situation in postmenopausal
women with osteoporosis and without inflammation.
Breast cancer research revealed a mitogenic tumor growth-stimulating role
of 16-hydroxylated estrogens, which indicates the potent estrogenic activ-
ity of these hormones.14 In vivo animal studies demonstrated a strong TNF-
increasing role of 16-hydroxyestradiol (estriol).15,16 Other conversion prod-
ucts of estrone and 17-estradiol are the 2-hydroxylated estrogens, such as
2-hydroxyestrone and 2-hydroxyestradiol. In contrast to 16-hydroxylated
estrogens, the 2-hydroxylated forms inhibit growth-promoting effects of
17-estradiol.17 Furthermore, the estrogen metabolism pathway favoring
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2-hydroxylation over 16-hydroxylation is associated with a reduced risk of
invasive breast cancer in premenopausal women.18 We can summarize that
16-hydroxylated estrogens are biologically active, proinflammatory, and pro-
proliferative, whereas the 2-hydroxylated metabolites act as naturally occurring
estrogen antagonists.
Apart from the very different metabolism of E2 to downstream estrogens
under inflamed and noninflamed conditions, the presence of glucocorticoids
may play an additional role for effects of sex hormones on proinflammatory cy-
tokine secretion from peripheral blood leukocytes and local macrophages. At
least on the level of the hypothalamus and pituitary gland, it has been demon-
strated that females mount a stronger hypothalamic-pituitary-adrenal (HPA)
axis response, and gonadectomy diminishes or abrogates this effect.2,19 It was
discussed that feedback inhibition by cortisol of the hypothalamus or the pitu-
itary gland may be modulated by sex hormones.2,19 The possibility that similar
interactions between sex hormones and cortisol occur in peripheral leukocytes
would have implications in understanding the known gender dimorphism of
the immune and neuroendocrine system.
In this study, we focussed on the role of testosterone and E2 on cytokine se-
cretion from human peripheral blood leukocytes in the presence and absence
of cortisol. For this pilot study, we used blood leukocytes because of their
availability in healthy subjects. Furthermore, we studied effects on cytokine
secretion caused by downstream E2 metabolites: 16-hydroxylated estrogens,
2-hydroxylated estrogens, and 4-hydroxylated estrogens. In addition, we inves-
tigated whether or not E2 and testosterone modulate glucocorticoid receptor
expression.
MATERIALS AND METHODS
Subjects and Blood Samples
For cytokine secretion studies, 9 (age 24–40 years) and, for analysis of glu-
cocorticoid receptor expression, 15 (24–40 aged) healthy male subjects were
recruited. All subjects were informed about the purpose of the experiments
and gave informed consent for further use of blood samples. Blood was drawn
in heparinized tubes between 9:00 and 10:00 AM and immediately processed.
Culture Conditions and Application of Sex Hormones and Cortisol
For cytokine secretion studies, a defined volume of whole blood was cul-
tured in 48-well plates together with serum-free medium (whole blood assay
in RPMI 1640 without phenol red, 0.57 mM ascorbic acid, Sigma Aldrich,
Taufkirchen, Germany). Preliminary assays demonstrated optimal cytokine
secretion when using 100 L of whole blood (for IL-2, IL-4, IL-10, IFN , and
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TNF) and 25 L of whole blood (for IL-6) in an end volume of 1,250 L (TA-
BLE 1). During the first 24 h, cells were incubated with vehicle, testosterone
(10−7 and 10−8 mol/L, Sigma Aldrich), E2 (10−8 and 10−10 mol/L, Sigma
Aldrich), 2-hydroxyestradiol (10−10 and 10−11 mol/L, Steraloids, Newport,
Rhode Island, USA), 2-hydroxyestrone (10−10 and 10−11 mol/L, Steraloids),
4-hydroxyestradiol (10−10 and 10−11 mol/L, Steraloids), 4-hydroxyestrone
(10−10 and 10−11 mol/L, Steraloids), 16-hydroxyestradiol (10−10 and 10−11
mol/L, Steraloids), and 16-hydroxyestrone (10−10 and 10−11 mol/L, Ster-
aloids). After 24 h, the culture medium was removed and substituted with
new medium without sex hormones, carrying lipopolysaccharide (LPS for
IL-6 stimulation, 0.5 ng/mL, Sigma Aldrich) or concanavalin A (100g/mL,
for stimulation of other cytokines, Sigma Aldrich), two strong immune stim-
uli, with or without cortisol (hydrocortisone, 10−6 mol/L, Pharmacia Upjohn,
Karlsruhe, Germany). We used cortisol at 10−6 mol/L because in preceding
whole blood assays with naturally available binding proteins this concentration
yielded half-maximum inhibition of TNF secretion (without cortisol: 109.1 ±
9.7 pg TNF/mL [100%] vs. with cortisol: 79.4 ± 5.1 pg TNF/mL [73%]).
These first assays also demonstrated that the observed decrease of about 27%
reflects the half-maximum effect of cortisol. After 12 and 24 h, supernatants
were taken and stored at −30◦C. TABLE 1 summarizes applied conditions.
For analysis of the influence of sex hormones on glucocorticoid receptor
expression, 30 mL of heparinized whole blood were cultured in 25 cm2 cul-
ture flasks (70 mL) for 24 h with vehicle, testosterone (10−7 mol/L), or 17-
estradiol (10−8 and 10−10 mol/L, Sigma Aldrich). In these experiments, no
cortisol was added. After 24 h, cultured cells were re-suspended, centrifuged,
treated twice with distilled water to remove erythrocytes, and washed twice in
phosphate-buffered saline (Sigma Aldrich). Then, leukocytes were lysed for
30 min in lysis buffer containing PMSF, SDS, NP-40, sodium deoxycholate,
and a mixture of protein inhibitors (“complete” from Roche Diagnostics,
Mannheim, Germany). After centrifuging, supernatants were stored at −30◦C.
Protein concentrations were measured using the BCA assay (reagents from
Sigma Aldrich).
TABLE 1. Mode of stimulation, use of whole blood, and observation time for different
cytokines
Volume of Observation
Cytokine WB [L] Stimulation Time [h]
IL-2 100 ConA 100 g/mL 24
IL-4 100 ConA 100 g/mL 24
IL-6 25 LPS 0.5 ng/mL 12
IL-10 100 ConA 100 g/mL 12
IFN 100 ConA 100 g/mL 24
TNF 100 ConA 100 g/mL 12
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Cytokine Determination in Supernatants
The cytokines IL-2, IL-4, IL-6, IL-10, IFN , and TNF were measured by im-
munometric enzyme immunoassays making use of antibody pairs (OptEIATM,
BD Pharmingen, San Diego, CA). In our hands, intra- and inter-assay coef-
ficients of variation were below 10%. The detection limit was approximately
4–20 pg/mL depending on the cytokine tested.
Western Blotting
Gels (Novex 8% Tris-Glycine, Invitrogen, Karlsruhe, Germany) were loaded
with 25 g of protein and, after electrophoretic processing, transferred to
nitro-cellulose. Membranes were blocked in Tris-buffered saline (TBS) con-
taining 2.5% of human serum protein and 2.5% of bovine serum albumin
(Biomol, Hamburg, Germany). Blots were then incubated for 1 h at room tem-
perature with primary antibodies against the human glucocorticoid receptor
(1:500 in 5% nonfat dry milk in TBS, Affinity Bioreagents, Golden, Colorado,
USA). Subsequently, membranes were washed in TBS and incubated with
secondary antibodies (1:1000 in TBS, horseradish peroxidase–conjugated,
Affinity Bioreagents). After another washing step, blots were developed using
chemiluminescent reagents (ECL+, Amersham Biosciences, Amersham, UK)
and then subjected to autoradiography. The films (Hyperfilm, Amersham, UK)
were scanned and analyzed using a densitometric method (Molecular Dynam-
ics, Amersham, UK).
Statistical Analysis and Data Presentation
Data are given as the mean ± SEM. Medians were compared by Mann–
Whitney test (SPSS/PC for Windows 11.0, SPSS, Chicago, IL).
RESULTS
Influence of Testosterone and E2 on Cytokine Secretion in the Presence
and Absence of Cortisol
In order to test the influence of testosterone and E2 on cytokine secretion,
we used physiological concentrations of these hormones in a relatively natural
microenvironment (whole blood). In the presence of cortisol, E2, in relation
to testosterone, at concentrations of 10−8 and 10−10 mol/L stabilized secretion
of TNF, IL-2, IFN , and IL-10 (FIGS. 1A, 1C, 1D, and 2B). For IL-6 and IL-4,
only E2 at 10−10 mol/L exerts similar effects (FIGS. 1B and 2A). E2 at 10−10
JANELE et al.: SEX HORMONES AND CYTOKINE SECRETION 173
FIGURE 1. Modulation of cytokine secretion by 17-estradiol (E2) and testosterone
in the presence of cortisol. Whole blood of five healthy male subjects was incubated in
triplicate with vehicle, testosterone, and E2 for 24 h at indicated concentrations. After 24 h,
medium was replaced and cells were stimulated with 0.5 ng/mL LPS (IL-6) or 100 g/mL
concanavalin A (TNF, IL-2, IFN ) for further 12 h (IL-6, TNF) or 24 h (IL-2, IFN ) in the
presence of 10−6 mol/L cortisol. Supernatants were removed and cytokines were measured
by enzyme-linked immunosorbent assay (ELISA). Means ± SEM are shown for TNF (A:
control = 79.4 ± 5.1 pg/mL), IL-6 (B: control = 857 ± 137 pg/mL), IL-2 (C: control =
289 ± 27 pg/mL), and IFN (D: control = 521 ± 49 pg/mL). ∗P < 0.05, ∗∗P < 0.01 versus
the respective concentration of testosterone.
mol/L stimulated IL-6 secretion in relation to vehicle (FIG. 1B). With respect
to other cytokines, E2 had no stimulating activity in relation to vehicle (FIGS. 1
and 2). In the absence of 10−6 mol/L cortisol, we observed very similar effects
for IL-2, IL-4, IL-6, and IL-10 (data not shown).
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FIGURE 2. Modulation of cytokine secretion by 17-estradiol (E2) and testosterone
in the presence of cortisol. Means ± SEM are shown for IL-4 (A: control = 94.5 ± 13.5
pg/mL) and IL-10 (B: control = 127.1 ± 8.4 pg/mL). Whole blood of five healthy male
subjects was incubated in triplicate with vehicle, testosterone, and E2 for 24 h at indicated
concentrations. After 24 h, medium was replaced and cells were stimulated with 100 g/mL
concanavalin A for further 24 h in the presence of 10−6 mol/L cortisol. ∗P < 0.05 versus
respective concentration of testosterone.
With respect to testosterone, in the presence of cortisol, this hormone at
10−7 and 10−8 mol/L inhibited secretion of IL-2, IL-4, and IL-10 (FIGS. 1C,
2A, and 2B), and it tended to inhibit TNF and IFN (FIGS. 1A and 1D) but
not IL-6 (FIG. 1B). Similar effects on IL-2, IL-4, and IL-10 were seen in the
absence of cortisol (data not shown).
Influence of Testosterone and E2 on Glucocorticoid Receptor Expression
Neither testosterone at 10−7 mol/L nor E2 at 10−8 and 10−10 mol/L changed
glucocorticoid receptor expression (FIG. 3).
Effects of Downstream Metabolites of E2 on TNF Secretion
Since metabolites of estrogens may modulate cytokine secretion, we investi-
gated effects of various metabolites of E2 and their combinations on TNF secre-
tion in the presence of cortisol. Metabolites were used in concentrations similar
to those E2 (or lower) because their maximum concentration is expected to be
equal to or lower than the concentration of the precursor E2. In the presence of
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FIGURE 3. Influence of testosterone and 17-estradiol (E2) on glucocorticoid receptor
expression in peripheral blood leukocytes. The values are given in percent densitometric
control, which is indicated by dotted horizontal line. The boundary of the box closest to
zero indicates the 25th percentile, a line within the box marks the median, and the boundary
of the box farthest from zero indicates the 75th percentile. Whiskers above and below the
box indicate the 90th and 10th percentiles. Black symbols give the individual values of
participating subjects (for T at 10−7 M = 9, for E2 at 10−8 M = 9, and for E2 at 10−10 M
= 6).
cortisol, all investigated metabolites at 10−10 mol/L did not change TNF secre-
tion (FIG. 4A). Thus, these effects were similar as compared to E2 (compare FIG.
1A). Interestingly, sole application of 2-hydroxyestradiol, 2-hydroxyestrone,
4-hydroxyestrone, or 16-hydroxyestradiol at 10−11 mol/L inhibited secretion
of TNF (FIG. 4A). Similarly, sole application of 4-hydroxyestradiol or 16-
hydroxyestrone tended to inhibit TNF secretion (FIG. 4A).
One molecule of E2 may be converted to different downstream metabo-
lites. In order to further delineate effects of combinations of estrogens down-
stream of E2, 16-hydroxyestradiol and 16-hydroxyestrone at 10−10 mol/L were
combined with the other metabolites. It is obvious that combinations of 16-
hydroxyestradiol (16OHE2) at 10−10 mol/L and 2- and 4-hydroxylated estro-
gens at 10−11 mol/L markedly increased TNF secretion (FIG. 4B). Thus, a
preponderance of 16-hydoxyestradiol over 2-/4-hydroxylated estrogens using
a ratio of 10:1 increased TNF secretion. A similar increase was observed
for the combination of 16-hydroxyestrone (16OHE1) and 4-hydroxylated
176 ANNALS NEW YORK ACADEMY OF SCIENCES
FIGURE 4. Influence of downstream metabolites of 17-estradiol (E2) on secretion
of TNF. (A) Influence of individual metabolites on TNF secretion. Control TNF was 54.1 ±
5.2 pg/mL. (B) Influence of combinations of metabolites on TNF secretion. Control TNF
was 21.8 ± 2.1 pg/mL. For both panels: Data are given as means ± SEM in percent
of control. ∗P < 0.05, ∗∗P < 0.01, +P < 0.001 versus control. Abbreviations: 2OHE2,
2-hydroxyestradiol; 2OHE1, 2-hydroxyestrone; 4OHE2, 4-hydroxyestradiol; 4OHE1, 4-
hydroxyestrone; 16OHE2, 16-hydroxyestradiol; 16OHE1 (= estriol), 16-hydroxyestrone.
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TABLE 2. Effect of the combination of 16-hydroxylated estrogens and 2-/4-hydroxylated
estrogens on secretion of TNF in the absence of cortisol.
16-Hydroxylated 2-/4-Hydroxylated TNF Secretion
Estrogen Estrogen (% of Control)
– – Control: 100 ± 4.2
16OH-estradiol 10−10 mol/L 2OH-estradiol 10−11 mol/L 91.4 ± 10.9
2OH-estrone 10−11 mol/L 77.7 ± 10.1
4OH-estradiol 10−11 mol/L 100.8 ± 7.6
4OH-estrone 10−11 mol/L 123.2 ± 16.5
16OH-estrone 10−10 mol/L 2OH-estradiol 10−11 mol/L 66.8 ± 5.7∗
2OH-estrone 10−11 mol/L 54.5 ± 6.8∗∗
4OH-estradiol 10−11 mol/L 104.1 ± 5.2
4OH-estrone 10−11 mol/L 119.5 ± 24.7
Data are given as means ± SEM.
Control TNF = 55.0 ± 4.5 pg/mL. ∗P < 0.01, ∗∗P < 0.001 for the comparison versus control.
metabolites but not for 2-hydroxylated estrogens (FIG. 4B). Such a stimulatory
effect of combinations of downstream metabolites was not observed in the
absence of cortisol (TABLE 2). In contrast, in the absence of cortisol, the com-
bination of 16-hydroxyestrone and 2-hydroxylated estrogens even inhibited
TNF secretion (TABLE 2).
DISCUSSION
This study showed dichotomous effects of sex hormones: E2 and metabolites
stabilized or increased cytokine secretion whereas testosterone inhibited this
secretion. This dual role of estrogens and testosterone on cytokine secretion
has been described in the literature and it was thought that this phenomenon
could explain the well-known female-to-male preponderance in acquiring au-
toimmune diseases, particularly when TNF and IFN play a dominant disease-
perpetuating role.1,3–5 However, two aspects have not been studied so far.
First, the additional role of cortisol for sex hormone modulation of cytokines
from peripheral blood leukocytes has been unclear. This can be important be-
cause these mechanisms may explain interactions of hormones on the level not
only of the pituitary gland, but also in peripheral inflammation. We demon-
strated that a stimulus of the HPA axis (injection of IL-1, ether anesthesia,
or granulomatous disease) led to stronger corticosterone responses in female
than in male mice,19 which corroborated a similar study in humans.20 Evidence
from the literature strongly supports the concept that estrogens enhance and
androgens diminish the glucocorticoid response to a variety of inflammatory
and noninflammatory stimuli. Although the mechanisms for these interac-
tions are not fully elucidated, there is strong evidence that sex steroids affect
the expression of glucocorticoid receptors in the central nervous system and
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modulate the negative feedback exerted by cortisol at the hypothalamus.2,19
These observations led us to hypothesize that cortisol interacts with testos-
terone or estradiol on the cellular level, which can be studied in humans using
peripheral blood leukocytes. This study demonstrates that E2 (in relation to
testosterone) stimulated production of TNF, IL-6, IL-2, IFN , IL-4, and IL-10
caused by the proinflammatory influence of applied immune stimuli (LPS and
Con A). The question arises as to how these findings may be linked to the
estrogenic support of the HPA axis response.
It has been demonstrated that the pituitary folliculo-stellate cell is a
macrophage type of cell located in the pituitary gland.21,22 This type of cell,
similar to peripheral blood monocytes/macrophages, can be stimulated by im-
mune stimuli in order to produce proinflammatory cytokines locally.23,24 Lo-
cally produced cytokines can act as secretagogues for ACTH and other pituitary
hormones.24 In this respect, the folliculo-stellate cell may be an important local
linking element between immune stimuli and hormone production.24 In this
present study, we have shown that E2 stabilized (in relation to testosterone)
or increased cytokine secretion induced by stimulatory agents in peripheral
blood cells. A similar effect upon the folliculo-stellate cell might explain the
facilitating effects of E2 on pituitary hormone secretion and the inhibitory ef-
fect of testosterone via an increase or decrease of locally produced cytokines,
respectively.
The second open question that was addressed in this study is the role of down-
stream metabolites of E2 on stimulated TNF secretion. Our results demonstrate
that the ratio of 16-hydroxylated estrogens in relation to 2-/4-hydroxylated
estrogens is important for TNF secretion. We were able to describe that a ra-
tio of 10:1 of 16-hydroxyestradiol in relation to 2-/4-hydroxylated estrogens
markedly stimulated TNF secretion in the presence of cortisol. This effect
was not observed in the absence of cortisol. Furthermore, in the absence of
cortisol, the combination of 16-hydroxyestrone and 2-hydroxylated estrogens
even strongly inhibited TNF secretion. These results delineate the importance
of downstream estrogens in respective concentrations. Again, this may play a
role not only on the pituitary level, but also in the peripheral immune response.
As pointed out in the introduction to this article, in persons with chronic inflam-
matory diseases, we observe a large shift toward 16-hydroxylated estrogens in
comparison to that measure in postmenopausal osteopenic women.9,10,12,13 Au-
thors in the field of rheumatology trust that estrogens exert proinflammatory
effects in most rheumatic diseases, whereas authors in bone research believe
that estrogens prevent osteoporosis through inhibition of cytokine secretion.
We suggest the following model to find an answer for this obvious discrepancy
(FIG. 5):
In the noninflammatory situation, an osteopenia-inducing milieu (FIG. 5,
left panel) is characterized by increased levels of 2-hydroxylated estrogens
and low levels of 16-hydroxylated estrogens.12,13 This balance would diminish
the basal secretion of TNF, IL-1, and IL-6 and, therefore, avoid bone loss
JANELE et al.: SEX HORMONES AND CYTOKINE SECRETION 179
FIGURE 5. Model of the estrogen influence on secretion of proinflammatory cytokines
in a noninflamed and chronically inflamed microenvironment. For abbreviation of estrogens
see legend to FIGURE 4. Left panel: In the noninflamed situation, an osteopenia-inducing
milieu is characterized by increased levels of 2OHE1/E2 and low levels of 16OHE1/E2. In
this situation, basal secretion of TNF, IL-1, and IL-6 is osteoclastogenic. However, TNF,
IL-1 and IL-6 are markedly lower than in chronically inflamed tissue. In such a situation,
administration of therapeutic estrogens probably increases the 2OHE1/E2 because this par-
ticular pathway is switched on. This would be a negative signal for the osteoclastogenic
TNF secretion. Right panel: In contrast, during chronic inflammation in the situation of
rheumatic diseases, such as rheumatoid arthritis, the balance is switched to 16OHE1/E2.
Under these conditions, one can assume that therapeutic administration of estrogens would
enhance 16OHE1/E2 over 2OHE1/E2, which would support secretion of proinflamma-
tory cytokines. Cortisol itself is a stimulator of aromatase, and somewhat elevated cortisol
concentrations in the tissue, although inadequately low in relation to inflammation, would
promote estrogen-induced secretion of proinflammatory TNF. Thus, under inflamed condi-
tions estrogens appear as proinflammatory agents whereas under noninflamed conditions
estrogens appear as anti-inflammatory.
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(for review see Ref. 6). In chronic inflammation (FIG. 5, right panel), adminis-
tration of therapeutic estrogens probably increases the 16-hydroxylated estro-
gens because this particular pathway is switched on. During estrogen therapy of
postmenopausal women without inflammation, the 2-hydroxylated estrogens
would appear in higher concentrations compared to 16-hydroxylated estro-
gens, which would be a negative signal for the osteoclastogenic TNF secretion
(FIG. 5, left panel). In contrast, during chronic inflammation in the situation
of rheumatic diseases, such as rheumatoid arthritis, the balance is switched to
estrogens and particularly to 16-hydroxylated estrogens (FIG. 5, right panel).
As shown in this study, a preponderance of 16-hydroxyestradiol versus 2-/4-
hydroxylated estrogens in the presence of cortisol markedly increased TNF
secretion. In this situation, one can assume that therapeutic administration of
estrogens would enhance 16-hydroxylated estrogens over 2-/4-hydroxylated
estrogens, which would support secretion of proinflammatory cytokines (FIG.
5, right panel). Cortisol itself promotes the conversion of androgens to estro-
gens.25 Therefore, somewhat elevated cortisol concentrations in the tissue26
would result in higher estrogen levels and, indirectly, increased secretion of
proinflammatory TNF. Thus, under inflammatory conditions estrogens appear
as proinflammatory agents.
In conclusion, this study on peripheral blood leukocytes demonstrated that
E2 stabilized or increased and testosterone inhibited immune stimuli–induced
secretion of proinflammatory cytokines, such as TNF and IFN . Furthermore,
combined application of 16-hydroxylated estrogens and 2-/4-hydroxylated es-
trogens in a ratio of 10:1 increased TNF secretion only in the presence of
cortisol. The findings of this study shed new light on the gender dimor-
phism of the neuroendocrine and immune systems. Furthermore, it demon-
strated that distinct cocktails of downstream E2 metabolites may induce pro- or
anti-inflammatory responses in blood leukocytes. Further studies in folliculo-
stellate cells and synovial cells of patients with rheumatoid arthritis are needed
in order to further elucidate the importance of these findings on the local level.
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